Finding the best tamoxifen dose to lower breast cancer risk
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests different doses of tamoxifen to find the best one for lowering breast cancer risk in premenopausal women. It aims to see if a lower dose works as well as the standard dose with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who has not gone through menopause yet.
- You are between 18 and 55 years old.
- You have a higher-than-average risk of breast cancer, confirmed by a doctor or risk calculator.
- You have not had breast cancer that spread (invasive breast cancer).
- You are willing to use birth control during the study.
- You can have mammograms or breast exams as part of the study.
- You have not taken tamoxifen or similar medications within the last 5 years, except for a short time.
- You have not had blood clots, certain cancers, or a double mastectomy.
- You are not pregnant or planning to become pregnant in the next 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether low-dose tamoxifen (a breast cancer prevention drug) or omega-3 supplements can lower breast cancer risk in postmenopausal women who are overweight and have a higher chance of getting the disease. The study lasts about 6 months and involves blood draws and a breast fluid test to see how the treatment affects breast cells.
This Phase 2 trial compares acolbifene and low-dose tamoxifen to see which better lowers breast cancer risk in premenopausal women at high risk. You would be followed with health visits, blood tests, and a breast tissue sampling procedure.
This trial compares two low-dose medications, exemestane and tamoxifen, to see which is better at preventing breast cancer in postmenopausal women who have a higher risk. You would take one of these pills daily for a few years, and the study will check how well it works and what side effects occur.
This trial is testing two low-dose hormone therapies (exemestane and tamoxifen) to see which works better for preventing breast cancer in postmenopausal women who are at high risk. It's a double-blind study, so neither you nor your doctor will know which drug you're taking.
This trial tests whether adjusting the dose of tamoxifen based on your body's processing can improve treatment for hormone-sensitive breast cancer. It aims to find the best dose for you while keeping side effects manageable.
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Hear when a new Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.